Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Nasdaq, S&P 500 slip from record highs as yields and oil rebound
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Assertio Therapeutics (ASRT) Tops Q4 EPS by 10c
March 6, 2019 4:04 PM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of $0.30, $0.10 better than the analyst estimate of $0.20. Revenue for the quarter came in at $62.8 million versus the consensus estimate of $60.91 million.
For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.
... More


